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ABSTRACT 
Mycobacterium tuberculosis (Mtb), the aetiological agent of tuberculosis (TB) is the leading 
infectious cause of death globally. The outcome of Mtb infection is variable and depends on 
host, bacterial and environmental factors. Mtb has evolved into a number of lineages and sub-
lineages exhibiting phylogeographical population structuring and diverse clinical 
consequences after infection. The Mtb Uganda genotype is the commonest cause of 
pulmonary TB (PTB) in Kampala, Uganda. Prominent inherited host factors that determine 
the outcome of TB are human leukocyte antigens (HLA).  
To investigate the impact of Mtb genomic diversity and host HLA allelic variability on the 
clinical outcome of TB infection in Ugandan patients, the clinical and pathological outcome 
of Mtb Uganda genotype, and the association between HLA II alleles and PTB due to Mtb 
were studied. The Uganda genotype was found less frequently in extrapulmonary TB (EPTB) 
than previously reported in PTB in the same setting (Paper I), and tuberculous lymphadenitis 
patients infected with Mtb Uganda genotype were significantly less prone to have abdominal 
lymphadenopathy (Paper IV). This may imply that Mtb Uganda genotype has reduced 
potential to disseminate. 
A study of the evolutionary relationships and worldwide distribution of the spoligotypes of 
Mtb isolates from Ugandan patients with tuberculous lymphadenitis indicated an ongoing 
evolution of the Uganda genotype, with Uganda at the center of this evolution (Paper II).  
HIV negative patients with pulmonary TB and their genetically related healthy household 
controls were typed for HLA class II alleles (Paper III). The HLA- DQB1*03:03 allele was 
significantly less frequent in patients compared to healthy controls suggesting that the HLA- 
DQB1*03:03 allele may be associated with resistance to TB.  
To establish the cause and pathology of fatal mycobacterial disease, the mycobacteria and 
pathology associated with fatal TB were studied (Paper IV). One quarter of fatal 
mycobacterial disease was associated with non tuberculous mycobacteria (NTM). Pleural 
effusions were significantly associated with Mtb disease compared to NTM infection (Paper 
IV).   
To explore the potential use of the CD4+ and CD8+ T cell immunoprofile to diagnose 
tuberculous effusion, CD4+ and CD8+ T cells from pleural effusions were characterized. 
CD4+ T cells were significantly more abundant in individuals with TB, and the 
CD4+/CD8+T cell ratios were significantly higher in tuberculous pleural effusion compared 
to non tuberculous effusion, however this significance was lost after adjusting for age and 
ethnicity. Analysis of pleural fluid for the quantity of CD4+ and CD8+ T cells may be useful 
for establishing a diagnosis of TB in suspicious cases (Paper V). 
In conclusion, this thesis highlights the genetic diversity of Mtb with Mtb Uganda as the 
predominant genotype in EPTB patients in Uganda. Both NTM and Mtb are associated with 
fatal mycobacterial disease and the pathology findings are indistinguishable, though NTM are 
significantly less likely to cause pleural effusion. Mycobacterial genetic diversity together 
with host HLA variability may have clinical consequences. This can be exploited in 
designing TB diagnostic, management and prevention strategies. 
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1 INTRODUCTION 
 
1.1 TUBERCULOSIS 
1.1.1 Historical overview 
The infectious nature of tuberculosis (TB) was first demonstrated in 1865 by a French 
physician, Jean Antonie Villemin, who demonstrated that rabbits inoculated with TB 
organisms developed the disease. TB has afflicted man for centuries though its etiology and 
infectious nature was first described by Robert Koch in 1892 [1]. The earliest evidence was 
of pulmonary and spinal TB in a 5-year old Egyptian mummy in 3400 BC. In Europe, TB 
infected between 70 and 90% of the urban population in the late nineteenth century [2]. 
George Canetti first published the results from early studies on the nature of various types of 
TB lesions in man during the 1940s. Based on autopsies of 1500 TB patients performed 
during a 7-year period, Canetti described three different features from a large variety of 
human TB lesions based on: (i) the histopathologic features of the lesion. (ii) the number of 
acid-fast bacilli observed by microscopic examination and (iii) the number of culturable 
bacilli on egg medium. He categorized the three different types of lesions in man further into 
various subtypes: (i) lesions characterized by marked inflammation including vasodilatation, 
edema, fibrinous exudate, and an influx of lymphocytes, (ii) lesions characterized by a 
cellular influx of monocytes transforming into giant cells which are characteristic of a 
classical granuloma or tubercle and (iii) lesions characterized by necrosis and 
homogenization. Necrotic lesions may remain solid with very few bacilli, and evolve to 
sclerosis, or the caseum may soften with accompaniment of enormous bacillary load, which 
he associated with the onset of clinical TB.  
 
1.1.2 TB Globally 
The World Health Organization (WHO) declared TB a global emergency in 1993, with a 
predicted mortality of 20 million people in a decade [3]. In 2014 TB was ranked alongside 
HIV as the leading infectious cause of death, accounting for nine million new cases and 1.5 
million deaths globally, 400,000 of whom were HIV positive [4]. About one-third of the 
world's population (1.7 billion) is estimated by WHO to be infected with Mtb. More than half 
of TB patients live in Asia and Africa [5]. Uganda is one of the countries with the highest TB 
burden in sub-Saharan Africa, and ranks 15
th
 among the 22 high-burden countries. The 
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annual TB incidence in Uganda is 559 cases per 100,000 [6].  TB is the leading cause of 
morbidity and mortality in individuals with HIV in sub-Saharan Africa [7]. Mortality rates of 
up to 40% per year have been reported in HIV patients co-infected with Mycobacterium 
tuberculosis (Mtb) on TB treatment [8]. According to WHO, 1.2 million people (13%) of the 
9.6 million people who fell ill with TB in 2014 were co-infected with HIV [4]. A significant 
number of patients with AIDS will have active TB, because the AIDS virus has a profound 
and detrimental effect on the immune response which normally controls the mycobacterium  
[9-11]. 
 
1.1.3 Pathogenesis of TB 
The majority of Mtb infected individuals do not develop active disease for many years. TB 
re-emergence and spread is determined by i) infectiousness of the infecting person (number 
of bacilli expelled in air), ii) TB exposure duration, iii) host susceptibility, and iv) virulence 
of the pathogen. Though Mtb is the predominant cause of TB, other species of the Mtb 
complex including M. africanum, M. Canetti, M. bovis, M. bovis BCG, M. microti, M. caprae 
and M. pinnipedii [12-14] may also cause disease. After infection with Mtb, the majority of 
infected people remain asymptomatic (latent TB), the infection being controlled by the 
immune response and no clinical disease develops [15]. Mycobacterial disease is also caused 
by various species of non-tuberculous mycobacteria (NTM). 
The risk for developing progressive disease is 5% annually (for 5 years) following primary 
infection [16]. This risk is 1.91% annually (for 5 years) following re-infection [16].  The 
lifetime risk of developing clinical TB is 10%, this however increases to an annual risk of 
over 10% in HIV infected individuals [17, 18]. The risk of developing primary TB is lower in 
children than adults [16], while children have a higher likelihood of developing severe 
disseminated TB than adults. Young women have an increased likelihood to develop active 
TB following infection than men of the same age [19, 20].  
Tubercle bacilli are transmitted from person to person through aerosols, small droplet nuclei 
size 5µ, 1-3 bacilli per nuclei generated during coughing, singing, laughing and sneezing. 
These droplets are expelled and lose moisture by evaporation, leaving a solid nucleus. 
Coughing is the most efficient method of generating droplet nuclei [21].  Particles less than 
5µm filter through the ciliated epithelium and end up in the lung alveoli [22, 23]. In the 
alveoli, the tubercle bacilli encounter the alveolar macrophages. An inflammatory process is 
initiated at the site of primary infection whose magnitude depends on the host immune 
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genetics, extrinsic immune system insults and virulence of the invading tubercle bacilli [24]. 
Concurrently, there is systemic dissemination of bacilli to other regions of the lung and 
organs. At this stage, active TB disease may develop if there is sustained proliferation of the 
bacilli.  
 
1.1.4 Immune system and mycobacteria 
TB infection has five stages based on rabbit studies [25]. The first onset stage begins when 
the bacilli are inhaled into the alveoli and phagocytosed by the non-specifically activated 
alveolar macrophages with eventual destruction [26]. Bacillary destruction is partially 
achieved resulting in the second stage called symbiosis [25]. During this stage, the bacilli 
multiply and reside in the macrophage without causing any progressive disease [27-29], the 
number of macrophages also increases but do not kill the bacilli. Activation of tissue 
damaging delayed-type hypersensitivity (DTH) with resultant caseous necrosis terminates the 
symbiotic stage.   
Annual Reviews
 Figure 1. Primary TB: Illustration of the trafficking of Mtb antigen by dendritic cells to 
regional lymph nodes leading to initiation of adaptive immunity by Cooper AM et al [30]. 
Permission granted by Cooper AM et al and Elsevier publishers. 
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The third stage is the caseous stage characterized by bacillary caseation and extensive cellular 
destruction at the centre of the granuloma or tubercle called caseous necrosis. The fourth 
stage involves dynamic equilibrium of tissue destruction and immune activation response. 
The fifth stage is liquefaction and cavity formation characterized by extensive destruction of 
granuloma tissue due to enzymatic activity. From the alveoli, the bacilli may be released into 
the environment through coughing or may invade into the blood stream resulting in 
dissemination. During this innate phase, the granuloma has been shown to be the epitome of 
pathogenic mycobacterial expansion and systemic dissemination [31]. 
The bacillary multiplication is usually controlled until the development of adaptive immunity 
in 3 to 8 weeks after primary infection [32]. Macrophages and dendritic cells provide a link 
between innate and adaptive immunity through receptor mediated interaction with Mtb. 
Numerous receptors expressed on phagocytic macrophages bind mycobacteria before their 
uptake [33]. These include C-type lectin receptors (CLRs), scavenger receptors (SR) and 
complement receptors [33]. The recognition of pathogen-associated molecular patterns 
(PAMP) by specific pathogen recognition receptors (PRRs) is pivotal to the initiation and 
coordination of the host innate immune response [34]. 
The PRR mediated macrophage phagocytosis includes Toll-like receptors (TLRs), 
nucleotide-binding oligomerization domain (NOD-) like receptors (NLRs), and C-type 
lectins. The C-type lectins include mannose receptor (CD207), the dendritic cell-specific 
intercellular adhesion molecule grabbing nonintegrin (DC-SIGN) and Dectin [35]. Interaction 
between PRR and PAMP result in intra- cellular signaling culminating in production of 
immune mediating pro-inflammatory cytokines like IL -1β, TNF-α and IL-6 [35-37].  
Dendritic cells and infected macrophages traffic to the regional lymph nodes to present 
antigen to naïve T cells in association with MHC class I and II or CD1 molecules, priming 
them against mycobacterial antigens [38].  
The T cells are activated, undergo clonal expansion and acquire effector functions [39, 40]. 
The Mtb antigenic specific T cell subset that directs the cell mediated response against TB in 
order of decreasing importance are CD4+αβ T lymphocytes, CD8+αβ T lymphocytes, γδ T 
lymphocytes and CD1 restricted αβ T cells [41]. These T cells can produce cytokines, kill 
antigen expressing cells in case of cytolytic T lymphocytes (CTL) and mobilize and 
potentiate other leukocytes (in case of T helper (TH) cells) the effector T cells migrate to the 
primary infection site (Figure 1). The cytokines functionally potentiate the resident 
macrophages and induce recruitment of more macrophages to the site of inflammation. The 
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activated macrophages though more efficient in killing the bacilli, do not completely 
eliminate them. This primary infection may reactivate later in life, a process called 
endogenous reactivation. In early phase of TB infection, the bacteria laden macrophages may 
cross the alveolar barrier to cause systemic spread [22, 42]. 
The intracellular proliferation of Mtb bacilli, their spread to lymph nodes and systemic 
dissemination occurs before the development of the adaptive immunity. In the majority of 
hosts, a cell mediated immune response that develops 2-8 weeks after the infection controls 
multiplication of the bacilli. The activated T lymphocytes, macrophages, and other immune 
cells constitute granulomas (Figure 2) that control further replication and spread of the 
tubercle bacilli [43]. Most Mtb are killed in the caseating granulomas. 
Primary TB infection occurs in individuals previously unexposed to Mtb or its antigens [44]. 
In the majority of patients, the primary TB is inhibited resulting in a standoff between the 
Mtb bacilli and the host.  The primary TB lesion is a ghon focus comprising foci of central 
necrosis surrounded by epitheloid macrophages and lymphocytes. Although in majority of 
cases the primary tuberculous caseous lesions heal with fibrosis and scarring, caseous 
necrosis may enlarge and progress. The dendritic cell traffic the bacilli to regional lymph 
nodes resulting in caseating granulomatous lymphadenitis, or the bacilli may systematically 
disseminate to result in disseminated or miliary TB.  
 A tuberculous lesion will progress into active disease or regress depending on the virulence 
and burden of the tubercle bacilli and the capacity of the macrophages to inhibit the growth of 
the bacilli. The main types of tuberculous lesions comprising proliferative and exudative 
lesions are described [45]. The proliferative lesions are characterized by a cellular influx of 
lymphocytes, plasma cells, fibroblasts, macrophages and langhan giant cells, morphologically 
forming a granuloma, while the exudative lesion is characterized by necrosis and 
homogenization [45]. 
Liquefied pulmonary caseous lesions or caseating lymph nodes erode into the air passages 
progressing into a spectrum of disease ranging from small pneumonic foci to lobar or 
bronchopneumonia. The extent of the resulting disease depends on the quantity of aspirated 
caseum and bacilli. 
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Annual Reviews
 Figure 2. Granuloma structure as depicted by Phillips JA et al [33]. Permission granted by 
the author and Elsevier Publishers. 
 
1.1.5 Tuberculous pleural effusion 
The immunological response during the development and progression of TB pleuritis occurs 
in three stages. The first stage is mediated by the production of IL-8 and monocyte 
chemotactic peptide (MCP-1) by activated mesothelial cells which acutely recruit 
polymorphonuclear neutrophils (PMNs) and monocytes [46].  PMNs and monocytes respond 
by secreting key cytokines such as TNFα, and IL-6. 
The intermediate stage follows in which CD4+ helper cells and CD8+ cytotoxic cells 
dominate culminating into a CD4+/CD8+ ratio of about 4.3 [47]. Finally, inflammation 
persists resulting in a sustained CD4+/CD8+ cell response, persistent INF-ϒ release and 
granuloma formation.  
 
 13 
 
1.1.6 Mtb and HIV co-infection 
HIV infection has a profound effect on the capacity to resist Mtb infection, and renders Mtb-
infected individuals susceptible to develop active TB [10, 11]. The hallmark of the HIV-
infection is the impairment of T cell functions and the ultimate loss of CD4
+
 T cells resulting 
in impaired ability of the host to mount an effective Mtb specific T cell response [11, 48-51]. 
Deficient maturation and function of CD8+ cytolytic T cells as well as deficient granuloma 
formation may reduce the control of latent TB [48, 52]. With regard to the innate immune 
response, several studies have addressed the ability of macrophages to control the growth 
and/or kill intracellular Mtb. However, data in this respect has been quite controversial [11]. 
 HIV infection is associated with impaired recruitment and function of macrophages to sites 
of TB infection resulting in deficient granuloma formation depending on the degree of 
immunosuppression [10]. HIV and TB infections fuel each other.  
 
1.1.7 Human leukocyte antigen 
One of the most intriguing aspects of this disease is that the outcome of an infection with Mtb 
is highly variable between individuals. There is evidence of multifactorial genetic 
predisposition in humans that influences the susceptibility to TB. The majority of infected 
persons (about 90%) will never develop the disease [53], the immune system apparently 
being capable of permanent containment of the infection. In the 10% of individuals who do 
develop active TB disease, this is usually after a latent interval that can vary from weeks to 
many decades. There is a whole spectrum of clinical presentations, ranging from subclinical 
to rapidly fatal and almost any organ can be involved. Evidence shows that there is 
multifactorial host genetic predisposition in humans that influences the susceptibility to TB 
[54].  
The adaptive immune system is regulated by the Major Histocompatibility complex (MHC), 
a locus on chromosome 6, of highly pleomorphic genes that encode for Human Leukocyte 
Antigens (HLA).  The MHC or HLA in humans comprises three sub-regions (Figure 3): the 
HLA class I region, encoding for HLA-A, -B, and -C antigens; the HLA class II region, 
encoding for HLA-DR, -DQ, and -DP antigens; and the HLA class III region, encoding for 
the second and fourth component of complement C2 and C4, factor B, tumor necrosis factors 
(TNF)-α and -β, heat shock protein 70, and 21-hydroxylase [55]. Class I and class II genes 
code for cell-surface glycoproteins that present antigenic peptides to CD8+ and CD4+ T cells 
respectively, and execute a pivotal function in the homeostasis of the immune response [56]. 
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Histocompatibility genes are inherited as a group (Haploid) from each parent, and are co-
dominantly expressed in each individual. A heterogeneous human being inherits one paternal 
and one maternal haplotype each with three Class I (A, B, C) and three Class II (DQ, DR DP) 
loci.  
In the class II locus, a person inherits a pair of HLA-DP genes (DPA1 and DPB1 genes which 
encode α and β chains respectively), a pair of HLA-DQ genes (DQA1 and DQB1 which 
encode α and β chain respectively), one gene of HLA- DRα (DRA1) and one or more genes 
of HLA DRβ (DRB1 and DRB3, DRB4, DRB5. 
HLA II present longer exogenous peptides ˃ 11 amino acid to CD4+ T Cells as compared to 
MHC I which present endogenous shorter peptides 8-10 amino acids [57] to CD8+ T Cells. 
The MHC class II is synthesized in the endoplasmic reticulum. Lysosomal proteases break 
down TB antigens into smaller peptides that bind with MHC class II. These peptide-MHC 
class II complexes are transported to the plasma membrane, where they are presented to 
CD4+ T cells. The T cell receptor recognition of the presented peptide initiates the generation 
of adaptive cellular immunity against TB [58]. Various HLA have been suggested to confer 
susceptibility or resistance to TB [59-61], and the genetic influence associated with the HLA 
system appears to influence the development of TB [61]. Much interest has focused on the 
HLA genes (notably the HLA-DR2 and HLA-DQB1 loci) that determine which 
mycobacterial antigens are presented to the helper T cells [62, 63]. 
The HLA system is a highly polymorphic biological system. The HLA system is a T cell 
restriction component associated with regulation of immune-responsive and immune-
suppressive genes [64]. Antigen-specific T cell responses require the presentation of 
processed peptides in context of MHC class I and class II cell-surface glycoprotein. Proteins 
encoded by class II MHC genes mediate the recognition of the antigen by regulatory T cells 
and are associated with immune recognition and response [65]. 
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Major histocompatibility complex
CLASS II                              CLASS II                                                 CLASS III    CLASS I
DP            DM              DQ              DR                      C4A     C4B       Bf           C2       TNF-α TNF-β
αβ αβ β α β β β α
LMP-2 TAP-1 LAP-7 TAP-2
B C E A H G F
Figure 3.  Genomic structure of the Major Histocompatibility Complex region 
 
Although an association between TB and HLA has been reported in many populations, 
results are inconsistent, the HLA associations with the different Mtb genotypes have not been 
explored and no studies have been done in the African population.  Studies using serology 
methods reported an increase of HLA-DR2 in TB [66-68]. 
 
1.1.8 Clinico-pathological features of TB 
The clinical outcome of TB infections depends on a number of factors: i) host factors 
including immune status, age, sex, co-existing diseases and nutrition and ii) pathogen factors 
like virulence of infecting bacilli and host- bacilli interaction. 
More than 85% of all tuberculous infections are pulmonary only, while the remaining 15% 
are extra-pulmonary or both pulmonary and extra pulmonary [69]. One important factor for 
the clinic-pathological outcome of the disease is HIV co-infection. One previous study of TB 
on patients with advanced HIV disease [70] revealed variable disease manifestations 
comprising  38%  pulmonary involvement alone, 30% extra pulmonary sites alone while 32% 
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showed both extra pulmonary and pulmonary manifestations. Extrapulmonary dissemination 
of TB disease increases with declining immune status [71]. 
 
Table 1. Clinical feature of TB with and without HIV [72].  
 
 HIV negative HIV positive 
Constitutional symptoms Common in both groups 
Extrapulmonary disease 0-30% 60% 
Pulmonary features   
Sub-apical disease Common Uncommon 
Cavitation Common Uncommon 
Lower lobe involvement Rare Common 
Diffuse or miliary Rare Common 
Diffuse or miliary Rare Common 
 
In a majority of people infected with tubercle bacilli, the disease is controlled resulting in a 
subclinical primary lesion (Figure 4) undetectable by chest X-ray but adequate to produce a 
tuberculin reaction. Progression of this primary lesion is halted by development of a delayed 
type hypersensitivity (DTH) reaction and cell mediated immunity (CMI). Secondary TB 
occurs as a result of reactivation of a primary tuberculous lesion or from exogenous source in 
individuals previously exposed to Mtb antigens [73]. 
Post primary TB develops from the exudative reaction and is typically restricted to the upper 
lobes of the lung. The exudative reaction is followed by a lipid pneumonia phase in which 
there is localized accumulation of foamy histiocytes in the alveoli at the periphery of the 
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upper lobe of the lung [74, 75] The alveoli increasingly become foamy and eventually 
degenerate leaving lipid debri [76]. 
Annual Reviews
 Figure 4. Pathogenesis of pulmonary TB as per Cooper AM et al [30]. Permission granted by 
Cooper AM et al and Elsevier publishers. 
 
Endobronchial TB with consequential bronchial obstruction is a constant clinical and 
pathological feature of post primary TB [77, 78]. Lipid pneumonia may progress to caseous 
pneumonia following necrosis [77, 79-81]. This necrosis is acellular, homogenized and 
associated with a marked increase in acid fast bacilli [80].The alveolar septa also undergo 
necrosis. 
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1.1.8.1  Pulmonary TB 
The systemic signs and symptoms include fever, night sweats, anorexia and weight loss [82]. 
The local symptoms include chest pain and cough which is the commonest local 
manifestation of TB. Cough may be initially unproductive but as inflammation and tissue 
necrosis ensues, it becomes productive. Occasionally patients may present with haemoptysis. 
Haemoptyisis may arise from a ruptured dilated vessel (Rasmussen’s aneurysm) in a 
tuberculous cavity wall, tuberculous bronchiectasis or erosion into an airway 
(broncholithiasis). 
 
1.1.8.1.1 Radiological features 
Radiological abnormalities are common in TB; however in HIV infection a normal X-ray is 
common. In primary TB, the abnormal radiological lesions are seen as middle or lower lung 
zone infiltrate associated with ipsilateral hilar lymphadenopathy. Secondary TB typically 
presents with radiological abnormalities in the upper lobe occasionally with cavitation. Hilar 
and mediastinal adenopathy is rare in immunocompetent adults but common in children. As 
the disease progresses, the infected material may spread through airways to produce patchy 
bronchopneumonia or may be aspirated downstream to produce bronchopneumonia. The 
parenchymal caseous lesion may erode into blood vessels and disseminate systemically as 
miliary TB. In HIV/AIDS patients, the radiological abnormalities depend on the degree of 
immunosuppression [83], and may present with both typical and atypical chest radiograph 
pattern, though patients with CD4+ T lymphocytes counts less than 200 cells/µl are likely to 
present with atypical radiographic appearance of pulmonary TB [83]. In more advanced HIV 
disease, atypical findings become more common, and lower lung zone infiltrates and intra-
thoracic adenopathy are common. Previous studies based on genotyping Mtb isolates showed 
similarities in radiological features between patients with primary TB and those with 
reactivated TB [84, 85]. Therefore, the prediction of the radiological appearance of TB does 
not depend of the duration between the acquisition of the infection and development of 
disease. The independent predictor of radiological appearance may be integrity of the host 
immune response, severely immune compromised patients tend to manifest with primary TB, 
whereas immune competent patients tend to have reactivated forms[84, 85]. 
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1.1.8.1.2 Primary pulmonary TB  
Radiologically primary PTB manifests as four main entities: lymphadenopathy, parenchymal 
disease, miliary disease and pleural effusion. 
Lymphadenopathy: Radiological feature of lymphadenopathy is detected in 96% of children 
and 43% of adults [86]. Lymphadenopathy is typically right sided and unilateral in the hilum 
and right para-tracheal region (Figure 5). In a third of cases, lymphadenopathy may be 
bilateral. Any lymph node greater than 2 cm is suggestive of active disease [87]. 
Parenchymal disease: At radiology, parenchymal disease in primary TB manifests as dense, 
homogeneous opacity predominantly in the lower and middle lobes. It can be distinguished 
from bacterial pneumonia on the basis of radiological evidence of lymphadenopathy. 
Miliary disease: Miliary TB clinically manifests in 1% to 7% of patients with all forms of TB 
[88]. It is more commonly seen in children, malnourished, individuals on immune 
suppressants, elderly and immune compromised person [88]. The classic radiological 
manifestation is evenly distributed small 2-3mm nodules randomly distributed throughout 
both lungs with intra and interlobular septal thickening [86], with slight lower lobe 
predominance. 
Pleural effusion: Pleural effusion occurs in one fourth of patients with primary TB and 18% 
of post primary TB [86]. Pleural effusions are usually observed in association with 
parenchymal or nodal disease, though occasionally they may be the only radiological finding 
indicative of PTB in approximately 5% of adults [89]. 
 
1.1.8.1.3 Post primary TB 
 Secondary or post primary TB refers to reactivation with or without re-infection of TB. The 
radiological features of primary and post primary TB may overlap. At radiology, the common 
manifestations of secondary TB include parenchymal disease, airway involvement and 
pleural extension. 
The earliest manifestation of parenchymal disease is patchy, poorly defined consolidation 
particularly in the apical or posterior segments of the upper lobe or superior segments of the 
lower lobe [90, 91]. 
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Figure 5. Para-tracheal lymph nodes. Photo Wamala D. 
 
 
 
Figure 6. Cavitation. Photo Wamala D. 
 
Cavitation affects about 50% of patients with post primary TB (Figure 6). The cavities have 
thick irregular walls. These cavities are usually multiple and may resolve to result in 
emphysematous changes or scarring. Lymphadenopathy and pneumothoraces manifests in 
5% of patients with post primary TB [91]. Tuberculous pleurisy is more common in primary 
TB than post primary TB [91]. 
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1.1.8.2 Extrapulmonary TB 
Extrapulmonary TB arises as a result of contiguous spread of Mtb bacilli to adjacent 
structures like pleura or pericardium, or by lympho-haematogenous spread during primary or 
chronic disease.  
 
1.1.8.2.1 Potential pathways for TB dissemination 
It is well established that Mtb can migrate from its primary infection site to the lymphatic and 
blood circulatory system. However the mechanism to achieve this is not clear.  
Haematogenous dissemination is a vital step in the pathogenesis of extrapulmonary TB. The 
bacilli traverse across the alveolar epithelial membrane by direct invasion and lysis of the 
epithelial cells. Mtb is capable of replicating intraepithelially and spread from cell to cell 
through the epithelial monolayer [92, 93]. There is evidence that Mtb is cytotoxic and causes 
cell necrosis which facilitates bacterial cell to cell spread [94, 95]. Bacterial cytotoxic factors 
have been identified in cellular modules. Early secretory antigenic target 6kDa (ESAT-6) and 
culture filtrate protein 10kDa (CFP-10) encoded by RD1 genes have been linked to 
macrophage and pneumocyte cytolysis [96-99]. Mycobacteria bind to sulphated 
glycoconjugates on epithelial cells using haemoglobulin binding haemagglutinin adhesion 
(HBHA) [100]. Mtb is also capable to invade and proliferate within endothelial cells [101]. 
Dissemination of Mtb is facilitated by mononuclear phagocytic cells, which traffic Mtb 
across alveolar walls [102]. 
A number of factors including the innate and adaptive immune response influence 
mycobacterial dissemination and development of extrapulmonary TB [103]. Dissemination of 
TB frequently occurs in people with single nucleotide pleomorphism in genes that encode for 
TLR-2 and Toll-interleukin 1 domain containing adaptor protein (TIRAP), a protein that 
mediates signals from Toll-like receptors activated by macrophages [104, 105]. Lipomannan 
and the 19kDa lipoprotein are agonists of TLR-2 pro-inflammatory cytokine signaling [106]. 
Extrapulmonary TB follows organ seeding with Mtb from mucosal or lympho-
haematogenous spread. Mucosal spread occurs especially in pulmonary TB patients with high 
bacillary loads. In chronic cavitary TB disease, highly infectious respiratory secretions that 
bathe the upper respiratory mucosa and gastrointestinal tract facilitate TB spread to laryngeal 
or gastrointestinal tracts respectively. Tuberculous pleurisy is the result of a delayed 
hypersensitivity response to Mtb antigen that gain access to the pleural space after rupture of 
a sub pleural caseous focus or tubercle bacilli access into the pleural cavity [107]. 
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1.2 THE PATHOGEN 
Host and environmental variables are important variables that determine the TB disease 
outcome. However, it is becoming evident that pathogen determinants and their interaction 
with the host and environment are important in the understanding of the pathogenesis of TB 
[108].  
Previous studies have clearly demonstrated the restriction of certain Mtb complex species to 
particular hosts and localities, Mtb, the primary causative agent of human TB; M. africanum, 
the main causative agent of human TB in West Africa [109]; M. bovis, which is responsible 
for bovine TB, M. microti, which is a pathogen of voles and rarely infects humans [110, 111]; 
M. canettii, an Mtb strain isolated from the horn of Africa [12, 112]; M. pinnipedii, also 
known as the seal bacillus [113-115]; and M. caprae which is primarily isolated from goats 
[116]. 
Previous observations also strongly suggest that clinical strains of Mtb vary in their virulence 
and immunogenicity [108, 117, 118], and these variations in pathogenesis of the various 
genotypes of Mtb have been associated with phenotypic consequences [119]. Some Mtb 
virulence factors may subvert the host innate immune response and augment the bacterial 
replication and pathogenicity.  Macrophages infected with an Mtb strain which caused an 
outbreak in Leicester, UK produced less protective IL-12p40 and more anti-inflammatory IL-
10. Mtb Beijing lineage strain HN878 caused several outbreaks of TB in Houston, Texas, 
USA between 1995 and 1998. This strain was found to cause rapid death in 
immunocompetent mice[120], while in rabbits it caused increased Mtb dissemination, more 
severe TB clinical manifestations and higher bacillary load [121]. The hyper virulence of 
HN878 was associated with inability to induce Mtb-specific T cell proliferation and IFN-γ 
production by the spleen and lymph nodes of infected mice. HN878 was also associated with 
2- to 4-fold lower levels of TNF-α, IL-6, IL-12 [120].There is also evidence to show that the 
early interaction between Mtb and the host depends on the Mtb lineage of the infecting strain 
[122].  
 
1.2.1 Mtb complex and Mtb genomic diversity 
Mtb genomic evolution has been attributed to mutation, deletions and transposition of 
chromosomal regions [126]. Through genetic characterization, various lineages or genotypes 
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of Mtb have been demonstrated (Figure 7) [127-130].  The Mtb complex comprises seven 
human-adapted distinct lineages which show strong phylogeographical population structuring 
[119]. The different lineages are associated with specific geographical areas (Figure 8) [131-
136].  For Mtb, more recent studies have further shown that specific genotypes are restricted 
to particular geographical areas, a phenomenon referred to as geographical sub-structuring 
[128, 137]. In addition, some genotypes of Mtb have been reported to be associated with TB 
affecting different organs in the host [138]. Despite high homology of the genome of Mtb 
complex members, these observations strongly suggest variations in pathogenicity of the 
various genotypes. In a study to assess differences in virulence between Mtb genotypes, a 
marked difference was observed in survival, lung bacterial load, lung histopathology, and 
cellular immune responses after infection of mice with different isolates from a spectrum of 
Mtb complex genotypes [54, 139].  
 
 
 
Figure 7. Evolutionary pathway of tubercle bacilli highlighting loss of DNA as shown by 
Brosch et al [123]. Permission from Diane Sullenberger Executive Editor, PNAS.  
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Figure 8. Distribution of the 5 lineages among the different regions of the world by 
geographic origin of the patients, picture by Perrin et al [124] based on data from Reed et al 
[125]. With permission from Pascale Perrin and Elsevier limited.  
 
Mtb genotypic diversity has been associated with variable clinical outcomes. The Mtb 
Beijing genotype can elude the host innate immune system which may explain why this 
genotype is associated with haematogenously disseminated disease[140] The Euro-American 
or East African lineages were significantly less associated with extrapulmonary TB [141]. 
Studies in Vietnam indicated that the East Asian/Beijing and Indo-Oceanic lineages were 
significantly more likely to cause disseminated TB than the Euro-American lineages and East 
Asian/Beijing and Indo-Oceanic lineages induced more macrophage TNF-α and IL-1β than 
the Euro-American strains in experimental models [122]. 
The Mtb complex, the aetiological agent of TB exhibits genomic diversity comprising seven 
phylogenetically related lineages [142].  Lineage 2 and lineage 4 (Euro American) are the 
most geographically widespread lineages [119]. The Euro-American Lineage is most 
prevalent in Europe and in the Americas. The Euro-American Lineage comprises 10 
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sublineages, each characterized by large sequence genomic deletions, namely RD 115, 
RD122, RD174, RD182, RD183, RD193, RD219, RD724, RD726 and RD761. The 11
th
 
group has no RD deletion (the so-called H#&Rv-like) [133]. The Euro-American lineage 
characteristically exhibits spoligotype deletion of spacer 33-36 in the DR locus [143, 144]and 
comprises the major families T, Haarlem, Latin American-Mediterranean (LAM), S and X, 
including a total of 34 subfamilies. 
By the phylogeny scheme proposed by Gagneux and colleagues [128], RD724 defines a 
major sub division within the Euro-American lineage of Mtb. Given the geographical long 
term predominance of RD724-positive Mtb in Kampala over the past two decades [145], the 
findings suggest that these strains may be specifically adapted to a Central African human 
host population, Ugandans included. These findings together with other studies [128, 132, 
135] indicate that each of the major lineages of Mtb have evolved to most efficiently transmit 
within an original human population. Some degree of co evolution has occurred as a result of 
long term association between Mtb complex and its human host [146].  
Previous studies have revealed a strong phylogeographical population structure exhibited by 
the human-adapted Mtb complex, with different lineages associated with particular 
geographical regions [132, 133, 136, 147-149].  In a study to determine the Mtb lineages of 
isolates from PTB patients from four continents, the distribution of Mtb lineages and 
sublineages varied by geographic region, Euro-American sublineage RD724 predominated 
among African region participants, whereas Euro-American other than RD724 predominated 
among non-African region participants. Previous literature suggests that distinct Mtb 
complex phylogenetic lineages cause disease in individuals of a particular genetic 
background. 
Mtb strains have adapted to original human populations, epidemiological studies suggest that 
different phylogenetic lineages of MTC might have adapted to different human population 
[146]. Studies have shown low levels of anti-TB drug resistance among the T2 MTC lineages 
[150]. Success of MTC lineages has been correlated with hypo-inflammatory phenotype in 
macrophages probably depicting their virulence [117, 119]. Previous work show that 
Lineages 2-4 exhibited a lower early inflammatory response compared to lineages 1 and 6 
[151]. This implies increased virulence of lineages 2-4(Euro-American lineage) and may 
explain their global dominance over other strains.  A delayed inflammatory response implies 
increased virulence and may be associated with successful predominance of these strains. 
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 With evidence of phylogeographical structuring of Mtb [128], it is no longer feasible to 
consider TB as a homogenous disease, but rather a spectrum. With increasing evidence that 
strain-to-strain variation can have important phenotypic consequences, phylogeographical 
strain variation might affect the development of new diagnostics, drugs, and vaccines [152]. 
This, therefore, may have both clinical implications as far as patient management and future 
diagnostic product design are concerned. 
Studies using single nucleotide polymorphisms (SNP) as molecular typing tool revealed a 
higher genetic diversity among Mtb complex than previously assumed, with potential 
variation in pathobiological phenotype outcome [153, 154]. 
1.2.2 Phylogeography of Mtb Uganda genotype 
In a study of a global collection of strains of Mtb specific deletions [128], TbD1 deleted 
strains were grouped into three families: the East-Asian (RD105-deleted), the East-African-
Indian (RD750-deleted) and the largest lineage, the Euro-American, with several deletions 
defining various sub-lineages. Among these Euro-American sub-lineages, strains collected 
from central Africa (3 from Uganda, 2 from Rwanda, 2 from Burundi and 2 from Central 
African Republic) were deleted for RD724. In Uganda, 139 strains that formed the 5 largest 
clusters of 344 spoligotypes from Kampala were analyzed at four loci: RD105, RD711, 
RD724 and RD750 [155]. All the strains evaluated were deleted for RD724 but conserved for 
the other three regions, confirming the predominance of a spoligotype and RD724-defined 
Mtb lineage in Kampala [127]. 
Mtb Uganda genotype has dominated in Kampala periurban region for over two decades 
[145]. Previous studies have revealed that Mtb Uganda genotype is the predominant cause of 
TB in Kampala, Uganda [127], but no evaluation has been done of its immunopathological 
phenotypic characteristics 
1.2.3 Molecular typing of mycobacteria 
MTBC comprises seven mycobacterial species causing TB, of which Mtb is a major 
causative agent of TB. Members of the Mtb complex share identical 16SrRNA sequence and 
nucleotide identity higher than 99.9% [156]. A number of molecular techniques have been 
developed over the past decade to characterize Mtb complex species and strains. 
Polymorphism of genomic DNA of Mtb complex has been exploited to differentiate clinical 
isolates [157].  
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The most popular molecular method used to differentiate MTBC was DNA finger printing by 
southern blotting of genomic DNA using a mobile entity IS6110 as probe [158]. Restriction 
fragment length polymorphism (RFLP) is based on variation in copy numbers and the 
differential genomic location of insertion sequence IS6110 and was previously the gold 
standard for Mtb complex genotyping [159]. IS6110-RFLP has limitations that include low 
reproducibility between different laboratories and requirement of large amount of good 
quality DNA. This has motivated the development of several PCR-based typing methods like 
spoligotyping that requires little DNA. 
Spoligotyping (spacer oligotyping) is a simple, cheap and quick PCR based method used to 
simultaneously detect and type Mtb exploiting previously observed polymorphism at the Mtb 
direct repeat (DR) locus [160]. This locus is composed of 36-base pairs (bp) DR interspersed 
with non-repetitive spacer sequences 34 to 41bp long [160]. Strains have variable numbers of 
DR and presence or absence of particular spacers [161]. In spoligotyping, DR region are 
targets for in vitro DNA amplification. The amplicons variable spacers are then visualized 
after hybridization to multiple spacer oligonucleotides covalently bound to a membrane and 
data digitalized.  
Genomic deletion analysis of regions of difference (RD analysis) has been used in 
supplementation with spoligotyping phylogenetic lineages [132, 133, 162, 163]. 
 
 
2 THE PRESENT INVESTIGATION 
 
2.1 PROBLEM STATEMENT 
Previous pulmonary TB studies have shown the predominance of Mtb Uganda genotype in 
urban Uganda [127, 164]. However, a comparison of the clinical, radiological and 
pathological features of the Uganda genotype strains with other genotypes of Mtb as well as 
their association with specific HLA types in the human population has not been studied. The 
role of the pathogen in the pathogenesis of EPTB and the clinical consequences of Mtb 
genomic diversity has not been fully explored.  This knowledge would be locally relevant in 
developing suitable vaccines and formulate locally appropriate disease prevention policies. 
The knowledge will also be valuable in patient management and prognostication. 
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2.2 THESIS AIMS 
The main goal of this thesis was to gain an insight in the pathogenesis and clinico-
pathological features of infection caused by Mtb Uganda genotype and other circulating non-
Uganda genotypes, with the hypothesis that Mtb Uganda genotype causes clinical 
pathological presentations different from those of other circulating Mtb strains. 
Specifically the aims are: 
 To study how the clinical, radiological and pathological features of disease caused by 
the Uganda genotype compare with other genotypes of Mtb in Uganda (Paper I). 
 To study the phylogenetical structure of Mtb isolated in patients with tuberculous 
lymphadenitis (EPTB) and how it differs from that of pulmonary Mtb isolates 
previously studied  (Paper II). 
 To identify HLA II DQ and DR alleles that may confer resistance or susceptibility to 
Mtb in general and Mtb Uganda genotype in Ugandan patients (Paper III). 
 To study the contribution of the different types of mycobacteria to mortality 
associated with mycobacterial disease (Paper IV). 
 To explore the diagnostic potential of CD4 T/CD8+ T Cell ratios in pleural 
tuberculous effusions (Paper V). 
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2.3 METHODS 
Table 2.  Summary of studies and methods used. 
 Main aim Study population  Specimen Diagnostic methods Genotyping 
Paper 1 To study the clinical, radiological and 
pathological features of disease 
caused by the Uganda genotype and 
other genotypes of Mtb in Uganda 
283 patients with 
lymphadenopathy 
FNA of lymph 
nodes 
Clinical, radiological 
assessment 
Cytopathological 
analysis, ZN and culture  
Spoligotyping 
RD analysis 
Paper 2 To investigate the phylogenetical 
structure of Mtb isolate in patients 
with tuberculous lymphadenitis   
121 patients with 
tuberculous 
lymphadenopathy 
FNA of lymph 
nodes 
ZN and culture Spoligotyping 
RD analysis 
Paper 3 To identify HLA II DQ and DR 
alleles in Ugandan patients with TB 
43 PTB 
42 healthy 
household controls 
Blood and 
sputum 
ZN and culture 
PCR based sequence 
specific oligonucleotide 
primers 
SpoligotypingRD 
analysis 
Immunogenetic 
typing 
Paper 4 To study the contribution of the 
different types of mycobacteria to 
mortality associated with 
mycobacterial disease 
49 mycobacteria 
culture positive 
autopsy cases with 
suspected TB 
Autopsy tissue 
biopies 
Pathological analysis. 
ZN and culture 
 
Spoligotyping 
RD analysis 
Study V To explore the diagnostic potential of 
CD4 T/CD8+ T Cell ratios in pleural 
tuberculous effusions 
35 TB patients  
43 non-TB controls 
Pleural effusion 
 
Culture and 
histopathological 
analysis 
Immuno-
cytochemical 
double staining. 
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2.3.1 Study area, patients and samples 
The studies were performed at Mulago Hospital Complex. Mulago Hospital is the National 
Referral Hospital with the largest number of TB patients. It also runs a Fine Needle aspiration 
clinic to which patients suspected to have extra-pulmonary tuberculosis lymphadenitis are 
referred from medical or surgical units.  
The laboratory studies for study I, II, III and IV were done in the Makerere University 
College of Health Sciences, Microbiology and Pathology Laboratories. The FNAs and 
autopsies were done in Mulago Hospital. Study V was conducted in Mulago-Kampala 
Hospital (patients) and Karolinska University Hospital, Huddige (Controls). 
Patients and samples are summarized in Table 2, and recruitment plan of patients in Figure 9. 
 
 
TB suspect (Mulago 
Hospital))
Lymphadenopathy-
FNAC
Patient
Lymphnode
ZN +ve/-ve
Culture
(+ve)
Genotype  
Spoligotyping
Post mortem 
subjects
Autopsy 
Examination 
ZN+ve/-ve
Culture –ve
(Excluded)
Culture –ve
(Excluded)
Clinical exam
HIV test
Radiology
CD4
HLA
Cytopathology
Blood Sugar
Haematology
tests
Clinical 
Findings
Recruitment Plan
 
Figure 9. Recruitment plan of patients for studies I, II and IV 
 
The ethical approval for all studies was granted by the Institutional Review Board of 
Makerere University College of Health Sciences. Written informed consent was obtained 
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from all enrolled study participants or their legal guardians including permission to use their 
samples’ isolates. 
2.3.2 Abdominal ultrasound scans  
Scans were performed with a MedisonSonoAce 9900 ultrasound machine (Seoul, Korea) 
using a 7.5mHz convex probe and a 7.5 mHz linear probe. The presence of abdominal 
lymphadenopathy was considered significant if there were more than three lymph nodes or at 
least one lymph node 12 mm or more in size. Lymph nodes were sought in the paraaortic 
region, the porta hepatis region, the mesentery and the splenic hilum. The role of abdominal 
ultrasound in diagnosis of extrapulmonary or disseminated TB was previously evaluated, and 
a significant correlation was found between abdominal lymphadenopathy and active TB as 
diagnosed by smear or culture [165],  thus abdominal ultrasound was found valuable in 
diagnosing  EPTB [166].  
2.3.3 Chest x-ray  
Posteroanterior chest x-ray was done in all TB cases and was performed with patients in 
standing posture and holding their breath, using a Schimadzu machine (Shimadzu-Japan), 
with the patient´s chest positioned 150cm away from the x-ray tube. The chest X-ray was 
considered abnormal when it showed any of the following: lobar/segmental consolidation, 
cavitation, fibronodular lesions, pleural effusion, hilar and/or mediastinal lymph nodes, linear 
interstitial disease or miliary disease. 
2.3.4 Immunocytochemistry of pleural fluid 
Thoracocentesis was performed for all patients with pleural effusion and symptoms of TB, 
including evening fevers, unintentional weight loss, cough and night sweats. Five ml of the 
pleural fluid was taken for cytology and immunocytochemistry, and a pleural biopsy was 
obtained. The biopsy was fixed in 4% buffered formalin, dehydrated in graded alcohol, 
embedded in paraffin, cut and stained with haematoxylin/eosin and ZN stain. 
The pleural fluid was centrifuged at 1000 rpm, making four slides of each sample with the 
cytospin technique. Three of these were stained with Diff Quick and according to 
Papanicolaou and ZN, respectively. The forth slide was fixed overnight in a PEG/ethanol 
fixative (60 g polyethylene glycol 1500, 500 mL ethanol, 500 mL methanol and 1000 mL 
distilled water). The slides were then stored at -20°C for later immunocytochemistry. 
  
 33 
 
Immunocytochemical double staining was carried out using the Leica Bond Immunostaining 
Instrument III. CD4 + cells were immunostained using the Bond polymer refine detection kit 
and CD8+ cells were immunostained with the Bond polymer refined red detection kit (Leica 
Biosystem Newcastle Ltd, Newcastle, UK). Briefly, the cytospin slides were fixed in 4% 
buffered formalin for 30 minutes and rinsed in PBS. Antigen retrieval was performed with 
citric acid buffer (pH 6) at 98°C for 5 minutes. The primary antibody to CD4 (NCL-L-CD4-
368, Novocastra, diluted 1:400) was then added and left to react for 30 minutes, followed by 
a secondary antibody 15 minutes. Endogenous peroxidase was blocked with H2O2for 10 
minutes with the peroxidase is attached via an antibody-polymer complex. Bound CD4 
antibodies were then visualized with diaminobenzidine (DAB)/H2O2for 10 minutes. Presence 
of the CD8 epitope is then demonstrated by 15 minutes incubation with the primary antibody, 
(Anti-human CD8clone C8/144B, M7103, DAKO, Copenhagen, Denmark, diluted 1:100), 
followed by incubation with a secondary antibody labelled with alkaline phosphatase for 20 
minutes, developing the reaction products according to the kit with Fast Red as chromogen. 
Slides were then counterstained with haematoxylin, dehydrated and mounted. Positive 
lymphocytes were counted manually. 
After immunocytochemistry analysis, CD4+, CD8+ and CD4+/CD8+T lymphocytes were 
determined in pleural effusions from patients with and without tuberculous pleural effusion 
(TPE) in order to establish a potential role for CD4+/CD8+ T cell ratio in establishing a 
diagnosis of TPE.  
2.3.5 Fine needle aspiration 
FNA was performed on consenting participants fulfilling inclusion criteria. Under aseptic 
conditions, the lymph node was immobilized with left hand to entirely access it while the 
right hand was used to aspirate. Using a 23G cutting needle and a 2 ml syringe lymph node 
aspiration was done with constant suction in a fan like fashion until the material appeared in 
the hub. The suction was then released, the needle withdrawn an. Lymph node aspirates were 
cultured for mycobacteria and cytologically analysed for features of TB including granuloma 
formation, necrosis, presence of AFBs as previously described [167].  
2.3.6 HLA Allele Typing  
Peripheral venous samples (4ml) were collected in EDTA vacutainers and stored at -80C. 
Plasma and peripheral blood mononuclear cell (PBMCs) were prepared according to 
standard techniques. DNA was extracted using a DNA purification kit, Epicenter 
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Biotechnology and was quantified to ascertain its presence using a GeneQuest as per the 
manufacturer’s instructions. (Model Number CE2302), and confirmed per extraction batch by 
agarose gel electrophoresis and bioimage visualization. 
HLA Class II typing by sequence-specific oligonucleotide probe hybridization was performed 
on the products. To analyze for the presence of a given allele, polymerase chain reaction 
sequence (PCR) for HLA- DR and DQ alleles was performed [168, 169] using an MJ-96 well 
thermocycler. Flanking sequences were amplified using alleleic primers based on a sequence-
specific oligonucleotide primers (SSP) principle. This was done using the One lambda Micro 
SSP DNA Typing kit according to the kit manufacturer’s instructions. The PCR-SSP 
methodology is based on the principle that completely matched oligonucleotide primers are 
more efficiently used in amplifying a target sequence than a mismatched oligonucleotide 
primer by recombinant Taq polymerase.  Primer pairs are designed to have perfect matches 
only with a single allele or group of alleles.  Under strictly controlled PCR conditions, 
perfectly matched primer pairs result in the amplification of target sequences (i.e., a positive 
result) while mismatched primer pairs do not result in amplification (i.e., a negative result).  
2.3.7 Post mortem procedure 
A complete body postmortem examination was performed on each of the subjects to study 
the pathological features of the inpatients suspected to have died of TB. The examination was 
performed within 24hrs after obtaining consent to avoid autolysis and delay in burial. All 
relevant information was reviewed before performing the postmortem examination including 
written clinical history, laboratory results and radiology. After external examination, careful 
attention was paid to ensure aseptic technique. Culture samples were collected in situ 
immediately after entering the bodies using sterile scalpel and forceps. Different sets of 
instruments were used for each culture. En masse (Letulle) evisceration was done followed 
by organ dissection and weighing as described [170]. Organs and regional especially matted 
caseating lymph nodes were inspected for disease, and representative tissue samples taken. 
Lungs were examined fresh for extent of disease by cutting sequentially along the arteries, 
airways and veins following the McCulloch and Rutty method [171]. Culture samples were 
put in sterile container containing 5ml of distilled sterilized water and transported on ice to 
the mycobacteriology laboratory at Makerere University School of Biomedical science. 
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2.3.8 Tissue analysis 
Samples for histopathology were taken from the lung, the spleen, the liver, lymph nodes, 
kidney, adrenals, brain and pancreas. All histopathology tissues were fixed with 10% formal 
saline, sectioned, dehydrated with graded alcohol, and cleared with xylene. The tissues were 
then embedded with paraffin wax to produce tissue paraffin blocks from which 4µm tissue 
sections were cut. The tissue sections were stained with haematoxylin and eosin (HE) for 
morphological analysis. Tissue sections were screened for AFB after staining with 
flourochrome (auramine) and ZN stains. Diagnosis of mycobacterial disease in the tissue 
sections was based on HE histological findings including chronic granulomatous 
inflammation, caseous necrosis and AFB positivity on ZN and auramine-rhodamine tissue 
staining.  Diagnostic criteria for NTM diagnosis in tissue samples was based on recognition 
of mycobacterial histopathologic features and positive NTM growth on tissue culture [172]. 
2.3.9 Mycobacterial identification and genotyping 
2.3.9.1 Culture and species identification 
In the mycobacteriology laboratory clinical samples were homogenized and disinfected with 
sodium hydroxide containing N-acetylcysteine prior to inoculation into Mycobacteria Growth 
Indicator Tube (MGIT 960) liquid culture for six weeks and on solid Loewenstein Jensen 
media for up to eight weeks culture. Once the culture was declared positive, preliminary 
smears were made and stained with ZN and Auramine-Rhodamine stain to confirm the isolate 
as AFB.   
DNA was harvested from growth following standard protocols [159] (Reagents from Sigma 
life Science, USA). DNA was the extracted from the cultured mycobacteria isolate following 
standard protocol [173, 174].  Isolates were identified by performing polymerase chain 
reaction (PCR)  using 16s reverse and 16s forward primers (Integrated DNA Technologies) 
targeting the 16s rRNA region with a conserved sequence typical for the genus Mycobacteria 
[175-177]. The Capilia TB assay (TAUN, Numazu, Japan) was used to distinguish Mtb 
complex  isolates from NTM [178], as per manufacturer’s instructions [179].  Mtb complex  
isolates were additionally identified by amplification of the insertion sequence IS6110 using 
an in-house PCR with aid of reverse and forward IS6110 primers (Integrated DNA 
Technologies).  Gel bands  of approximately 500 bp signified positive results [180]. 
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2.3.9.2 Spoligotyping 
Molecular characterization was done of Mtb isolates using DR analysis and spoligotyping 
following standard protocol [175, 181] and manufacturer’s instructions (reagents from 
Ocimum Biosolution, custom Master Mix from ABgene).  Spacers were visualized on film as 
black squares after incubation with streptavidin-peroxidase and ECL chemiluminescence 
detection reagents (RPN 2105 Amersham, GE Healthcare Bio-sciences). The spacer 
hybridization patterns were converted into binary and octal format as previously described 
[182]. The 43-digit binary code was converted to 15-digit octal code (base 8, having the digits 
0-7) [182]. The binary codes of the isolates were entered into the SITVIT2 database of the 
Pasteur Institute of Guadeloupe and assigned specific shared international spoligotype 
signatures (SIT) according to the SITVIT2 database [183].  
2.3.9.3 Region of difference (RD) analysis  
Mtb complex isolates were typed using a PCR based typing method [175] which depends on 
chromosomal region of difference (RD) deletion loci. The patterns of amplification products 
are visualized by agarose gel electrophoresis. RD 9 confirmed that the cases were Mtb and 
ruled out other species, RD4 and RD 14 ruled out M. bovis, the RD724 deletion is 
characteristic of Uganda genotype. 
2.3.9.4 Identification of Uganda genotype 
The Uganda genotype, a sublineage of the T2 lineage, was identified by deletion of  RD724 
on RD analysis [184], and absence of spacers 33-36 and spacer 40 and/or 43 on spoligotyping 
[185, 186].  
2.3.10 Statistical methods  
Paper I Crude and multivariable logistic regression analysis was used to explore clinical, 
radiological and pathological features of Mtb Uganda genotype compared with those of M.tb 
non-Uganda genotype. Independent sample t-test was used to compare means of continuous 
variables. 
Paper II. Spoligotyping data were digitized and analyzed with the BioNumerics software, 
version 5.0 (Applied Maths, Kortrijk, Belgium). 
Paper III, Fisher’s exact test was used to find associations between the patients belonging to 
certain HLA types and the risk of clustering with “Mtb Uganda genotype”. P-values 
were adjusted for multiple comparisons using the Benjamini and Hochberg method. 
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Paper IV. Univariate and multivariate data analysis was performed and logistic regression 
models were used to adjust for confounders like age, sex and HIV status. Chi square and 
Fisher’s exact test were used. The independent-samples t test was used to analyze quantitative 
data for a two sample case to compare means.  
Paper V. The utility of the test to distinguish the TPE from the non-tuberculous effusions was 
monitored by ROC plot. Comparisons of group means were performed with the Student’s t-
test. A two-by-two contingency table test with Yate’s correction for continuity was used to 
evaluate a possible correlation between the proportions of CD4+ reactive cells and patient 
group. The differences between TPE and non tuberculous effusion CD4:CD8 T Cell ratios 
were adjusted for confounders using linear regression. 
 
3 RESULTS AND DISCUSSION 
 
3.1 PAPER I  
The study population comprised patients presenting with clinical features of TB and 
peripheral lymphadenopathy. Mtb genotyping was done using spoligotyping and RD analysis 
of Mtb culture isolates. 
283 patients with superficial lymphadenopathy were enrolled. Of those 150 (53%) lymph 
node aspirate cultures turned out negative, 121 were culture positive for Mtb, 9 samples were 
ZN positive but culture negative, 6  samples were contaminated, and six samples were culture 
positive for mycobacteria other than Mtb. 
Mtb Uganda genotype, a member of the T2 Euro-American lineage, was the predominant 
genotype isolated from Uganda patients with tuberculous lymphadenitis, accounting for 46% 
of all cases. This frequency was lower in comparison to the 70% prevalence of the Uganda 
genotype seen in PTB patients in the same setting [127].  
Tuberculous lymphadenitis patients infected with Uganda genotype strains were significantly 
less prone to present with abdominal lymphadenopathy (p = 0.014) than those patients 
infected with non-Uganda strains (Table 3), even after adjusting for confounding factors 
including age, sex and HIV co-infection (p = 0.046). Abdominal lymph node enlargement 
was itself significantly associated with abnormal chest X-ray findings (p = 0.027) (Table 4).
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Table 3. Clinical and immunopathological parameters of patients infected with Uganda 
genotype and those infected by non-Uganda genotypes of Mtb. 
Patient characteristics Uganda/Non-Uganda  
n (%) 
Crude Adjusted 
OR (95% CI) P-value OR (95% CI) P-value 
Clinical presentations      
    Fever less than 6 months 39(70%)/44 (69%) 1.0 (0.5-2.3) 0.916 1.1 (0.5-2.5) 0.870 
    Night sweats 43(77%)/55(86%) 0.5 (0.2-1.4) 0.200 0.5 (0.2-1.4) 0.213 
    Cough 27(48%)/30(46%) 1.1 (0.5-2.2) 0.821 1.4 (0.7-3.1) 0.435 
Radiological Presentations      
    Abnormal Chest X-ray 20(43%)/27(47%) 0.8 (0.4-1.8) 0.624 0.8 (0.4-1.9) 0.644 
    Abdominal lymphadenitis 21(38%)/39(60%) 0.4 (0.2-0.8) 0.014 0.5 (0.2-1.0) 0.046 
Lymph node Pathology      
    Single site lymphadenitis 34(62%)/32(50%) 1.6 (0.8-3.4) 0.197 1.4 (0.6-2.9) 0.435 
    Generalized lymphadenitis 5(9%)/11(17%) 0.5 (0.2-1.5) 0.204 0.7 (0.2-2.1) 0.474 
    Lymph node ≥ 4 cm 15(28%)/28(45%) 0.5 (0.2-1.0) 0.055 0.6 (0.3-1.3) 0.157 
    Necrosis 52(93%)/61(94%) 0.9 (0.2-3.6) 0.827 0.8( 0.2-3.4) 0.741 
    Giant cells 28(50%)/25(38%) 1.6 (0.8-3.3) 0.203 1.3 (0.6-2.8) 0.569 
    Macrophages 53(95%)/58(89%) 2.1 (0.5-8.7) 0.290 1.5 (0.4-6.9) 0.577 
    Granulomas 47(84%)/46(71%) 2.2 (0.9-5.3) 0.091 1.9 (0.8-4.8) 0.196 
    ZN positive smear 29(52%)/42(65%) 0.6 (0.3-1.2) 0.152 0.7 (0.3-1.5) 0.348 
Adjusted* = Adjusted for Age, Sex and HIV status; OR = Odds ratio, Cl = Confidence 
Interval. Logistic regression. 
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Table 4. Association of abdominal lymph node enlargement with features indicative of TB 
dissemination (i.e. generalized lymphadenopathy, abnormal chest X-Ray, AFB positivity 
and absence of granuloma). 
 
 Abdominal  
Lymphadenopathy  
n = 60 (49.6%) 
Non-Abdominal  
lymphadenopathy  
n = 61 (50.4%) 
P-Value 
Generalized Lymphadenopathy: 
Present 30 (57%) 23 (43%) 
0.170 
Absent 20 (39%) 19 (30%) 
Granuloma: 
Present 46 (50%) 47 (50%) 
0.960 
Absent 14 (50%) 14 (50%) 
Abnormal findings on Chest X-ray: 
Present 30 (64%) 17 (36%) 
0.027 
Absent 24 (41%) 34 (59%) 
AFB smear positivity: 
(ZN or fluorochrome stain) 
Positive 39 (65%) 29 (47%) 
0.053 
Negative 21 (35%) 32 (53%) 
Chi-square test. 
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In line with these findings, lineage 4 (Euro-American lineage), to which Uganda genotype 
belongs, has been associated with pulmonary TB [105], while the East Asian/Beijing and 
Indo-Oceanic lineages were significantly more likely to cause disseminated TB [105]. 
Lineage 4, to which the Uganda sub-lineage belongs shows enhanced transmissibility in 
human populations [117, 119]. 
 
3.2 PAPER II 
Lymph node isolates from the 121 patients with tuberculous lymphadenopathy in study I 
were further analysed by spoligotyping. and the evolutionary relationship and worldwide 
distribution of the spoligotypes was assessed (Fig 10). The isolates were exclusively Mtb and 
lineage 4, also known as the Euro American lineage, was the predominant cause of EPTB in 
Uganda, As shown in paper I the Uganda genotype was the predominant genotype, although 
at a lower frequency than in studies of PTB in the same setting. The spoligotypes were in 
most cases similar to those causing PTB with the exception of SIT420 and SIT53 that 
predominated in this study but are mainly lacking in other studies of PTB.  
Exploring the Mtb diversity is essential in appreciating the clinical manifestation and 
pathogenesis of the disease as well as the rationale for development of new diagnostic 
strategies. The phylogenetical analysis and the study of the worldwide distribution of 
clustered spoligotypes indicate an ongoing evolution of the Uganda genotype, with Uganda at 
the center of this evolution. 
 
 
 
 
  
 41 
 
 
 
 
Fig 10. Phylogenetical analysis illustrating evolutionary relationships between Mtb 
spoligotypes in Kampala, Uganda (n=121 isolates). (A). Minimum Spanning Tree (MST) 
constructed on all isolates. Separations between the nodes represent the number of strains 
shared by a given spoligotype pattern. The links between nodes indicate the distance (darker 
and bolder lines mean a unique change whereas finer gray lines, continued, dotted or dashed, 
indicate more changes). (B). Spoligoforest tree drawn as a hierarchical layout; and (C) 
spoligoforest tree drawn using the Fruchterman-Reingold algorithm. Loss of spacers is 
represented by directed edges between nodes, and the arrowheads point to descendant 
spoligotypes. Solid black lines link patterns that are very similar, i.e. loss of one spacer only 
(maximum weight being 1.0), while dashed lines represent links of weight comprised 
between 0.5 and 1, and dotted lines a weight less than 0.5. 
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3.3 PAPER III 
In this matched case control study, HLA class II (HLA-DR and -DQ) allele frequencies in TB 
patients were compared with those in healthy, ethnically and geographically matched 
controls. 
Two groups, patients and controls were recruited. HIV-negative patients (n=43) were selected 
from newly presenting ZN smear positive patients. Controls (n=32) were recruited from 
people previously exposed to TB having neither signs /symptoms of TB nor ever developed 
clinical signs of TB visiting the same facility for minor complaints. 
There was a negative correlation between the HLA- DQB1*03:03 allele and susceptibility to 
TB (P = 0.003) indicating that this allele may confer protection against TB in the study 
population Even after correction for multiple testing the absence of the HLA-DQB1*03:03 
allele in all TB patients was still found significant. 
The more common HLA II alleles isolated here were not associated with TB susceptibility or 
resistance may imply that the Mtb bacilli and the local host have undergone a genetic co-
evolution to ensure that the Mtb pathogen thrives and persist in the local population. The 
HLA II DQB1:03:03 allele which apparently confers protection against TB are few meaning 
probably that they are new emerging alleles in the community. Host-pathogen co-evolution 
favors Mtb pathogens that avoid presentation by the most common HLA molecules in the 
host population, this results in selection for the host with rare HLA alleles conferring 
resistance to the Mtb pathogen. The frequency of rare but protective HLA alleles will 
increase whereas the dominant HLA alleles will become less frequent resulting in dynamic 
polymorphism [187, 188]. Unfortunately Mtb pathogens mutate faster than the MHC of their 
host [189]. 
The finding of a negative correlation between the HLA- DQB1*03:03 allele and 
susceptibility to TB (P = 0.0025) indicate that this allele may confer protection against TB in 
the study population. This is supported by previous observations that an effective immune 
response in terms of IFN-γ production was elicited when peptide T1, a component of CFP-10 
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was presented to CD4 T cells in the context of DQB1*03 [190]. CFP-10 is a potent T cell 
antigen that is recognized by many individuals infected with Mtb [190]..  
 
MHC polymorphism imposes a limitation of developing a universal vaccine against 
infectious diseases, because an effective T cell response is dependent on an individual MHC 
phenotype [191]. Knowledge of the HLA types present in a target population and the 
particular epitopes that are restricted by these HLA types enables synthesis of optimally 
immunogenic MHC-based vaccines [192], specifically tailored  for the target population 
[193]. The anti-Mtb immune response is a bias towards CD4+ T cells [194]  viewed as 
crucial for anti-Mtb immune responses.  
 
3.4 PAPER IV 
In an autopsy study of patients (n=49) with presumptive TB who were culture positive for 
mycobacteria at autopsy a majority of cases (75%) were caused by Mtb, of which 16 (55%) 
were Uganda genotype. In 25% of patients NTM were identified. Although the 
histopathological findings in most TB cases were severe, 38 (76%) of the patients that were 
diagnosed with TB on autopsy had not been diagnosed before death. As expected 
extrapulmonary TB was significantly more prevalent among patients with HIV than among 
those without, while cavitating TB lung disease was significantly less prevalent among 
patients with HIV. Histopathology was similar in TB and NTM patients, although NTM 
patients had significantly reduced tendency to cause pleural effusions.   
The genus Mycobacterium comprises more than 120 species including human pathogens 
[195]. Mtb is considered to be the principal cause of mycobacteriosis in humans [24]. 
Although speciation of the NTM isolates could not be performed, the results indicate that 
some NTM species may contribute to mortality. NTM has also been reported as an important 
cause of mortality in the United States with a significant increase in NTM related death from 
1999 through 2010 [196]. In the same study, pleural effusions were not significantly 
associated with NTM. This is in agreement with a previous study in Taiwan in which 
tuberculous pleural effusion was significantly more associated with PTB than NTM 
pulmonary infection [197]. Also in Portugal and Brazil an increase in NTM infections has 
been observed [198].  
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NTM in general cause clinical disease in individuals with acquired and inherited 
immunodeficiency disorders. However, in this study we found mycobacteriosis due to NTM 
not only in HIV positive patients but also in HIV negative patients. Previous studies have also 
reported mycobacteriosis due to NTM in HIV negative patients [199].  
The pathological findings at autopsy were similar in patients infected with Mtb and those 
infected with NTM, though pleural effusion was significantly associated with Mtb infection. 
NTM in general exhibit low virulence and pathogenicity compared to Mtb, with a low 
tendency to elicit an immunological reaction needed to generate a pleural effusion.  
The presence of AFB in ZN stained smear or tissue may signify preliminary diagnosis of Mtb 
infection but can also represent NTM [200]. A positive AFB test is thus not specific for Mtb 
complex [201-203].  Mtb is the leading cause of infectious morbidity due to bacterial 
pathogen globally. Mortality in our case was mainly attributed to late or missed TB diagnosis. 
The diagnosis of disseminated and extrapulmonary TB is quite elusive because of the lack of 
classical features of TB. It is important for physicians to have a high degree of TB suspicion 
in patients present with pyrexia of unknown origin. Early diagnosis is pivotal to strategies 
designed to reduce transmission and morbidity due to Mtb. NTM should also be identified in 
all patients with mycobacterial infection because of the clinical implications associated with 
NTM. In comparison to Mtb NTM require a more prolonged course of therapy with a 
combination of drugs [204].  
3.5 PAPER V 
Thirty-five adults suspected of having TB and 43 control subjects without TB but with 
pleural effusions from other causes were recruited. The diagnosis of TPE was established 
when the ZN stain or Lowenstein-Jensen culture was positive for TB or when granuloma 
were shown in the pleural biopsy. 
Pleural fluid CD4+ T cells were significantly more abundant in individuals with TB and TPE 
patients had a significantly higher CD4+/CD8+ ratio compared to non-TB patients and 
controls at unadjusted analysis. However age and ethnicity were found to be important 
confounders and the CD4+/CD8+ T cell ratio varied considerably among those with TPE.  
Analysis of pleural fluid for the quantity of CD4+ and CD8+ T cells may be useful for 
establishing a diagnosis of TB in suspicious cases.  The gold standard for diagnosis of TPE is 
detection of Mtb in pleural fluid or pleural biopsy specimens by microscopy or culture. In 
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pleural tissue biopsy, one needs to demonstrate granulomatous inflammation along with 
AFB. The diagnostic yields of pleural effusion is 12 -70% for culture [205-207] and 65 -82% 
for histological examination [208-211], but pleural biopsy is expensive in most of low 
resource countries.  
Previous studies have assessed the use of serum CD4+ and CD8+ immunoprofile in 
diagnosing TPE. The typical pathogenesis model involves a rupture of sub-pleural caseous 
foci followed by a delayed hypersensitivity reaction to Mtb antigens [212-214]. Previous 
work has established that there are distinct differences between the circulating immune 
profile and the pleural fluid in HIV/TB patients [215].  The TPE is generated from a localized 
immune response occurring in the lung; hence analysis of the peripheral blood may not be 
representative of the host immune response, particularly at the acute stage of disease. 
Evidence shows that immune cells sequester to the lung during TB [216-220]. In conclusion 
this study indicates that the CD4+/CD8+T Cell immunoprofile may be used to discriminate 
between TPE and non-TPE though the sensitivity may be reduced by confounders like age 
and ethnicity.  
 
4 CONCLUDING REMARKS AND REFLECTIONS ON 
LEARNING OUTCOMES 
This thesis set out to explore the influence of strain genomic diversity, and in particular the 
Mtb Uganda genotype, on the clinical phenotypic outcome of infection with Mtb in Uganda. 
The studies here further support the dominant role of the Uganda genotype in the ongoing TB 
epidemic in Uganda.  
The finding that Mtb Uganda genotype was less frequent in EPTB cases than previously 
described in PTB patients in Uganda [127], in combination with the observation that 
tuberculous lymphadenitis patients infected with isolates of Mtb Uganda genotype were 
significantly less prone to have abdominal lymphadenopathy may indicate a reduced ability 
of Mtb Uganda genotype to cause extrapulmonary disease. Since efficient Mtb transmission 
depends on lung damage, bacterial genotypes that are more prone to cause pulmonary disease 
may transmit more efficiently and tend to be dominant. 
There was a negative correlation between the HLA II DQB1:03:03 allele and susceptibility to 
PTB, even after correction for multiple testing, indicating that this allele may confer 
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protection against PTB in the study population. The dominant HLA II alleles were not 
associated with TB susceptibility or resistance implying that the Mtb bacilli and the local host 
have undergone a genetic co-evolution to ensure that the Mtb pathogen thrives and persists in 
the local population.  
The study adds more evidence to previous observations that genetic diversity within Mtb has 
clinical and phenotypic consequences. This has practical consequences for designing 
diagnostic and drug susceptibility testing molecular methods, and for the use of current 
antibiotics. Knowledge of the locally prevalent HLA profiles could be used in designing 
locally customized effective HLA based vaccines. Analysis of pleural fluid for the quantity of 
CD4+ and CD8+ T cells may be useful for establishing a diagnosis of TB in suspicious cases. 
The work has increased awareness of the importance of molecular methods in the 
management of TB among physicians, and has built both technical and human capacity in 
molecular diagnostic methods. The molecular methods I learned here will be extended to 
improve the diagnostic accuracy of cancer and cancer gene mutations at the Pathology 
Department in order to offer personalized oncology treatment.  
As Mulago Hospital prepares for a renal transplant program, this work has demystified 
immunogenetics and has generated protocols for the new hospital Transplant and 
Immunogenetics laboratory.  
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